Increase font size   Decrease font size   Print-friendly view   Print

Pharma Phacts: In the Media


Just an update from the phriendly pholks at Pharma Phacts.

Read on about the Vioxx trial that has been happening down in Melbourne this year.

Join the discussion topic to voice your views.

Case shines light on Merck

Milanda Rout | June 27, 2009
Article from: The Australian

WARREN Back received his instructions by telephone at 5.30pm on September 29, 2004, sitting in his nondescript hotel room in the US city of Philadelphia. He was told to collect a series of envelopes and distribute them to his international colleagues who had already gathered in the hotel for a conference, and keep one for himself.
Inside his envelope was a typed message telling him to go back to his hotel room and wait by the phone to receive a call from his superiors. He took the call two hours later and was stunned by what he heard.
This may sound like an elaborate plot of a spy thriller but Back was no CIA agent and he was not trading state secrets. Back was the Australian regulatory affairs manager for pharmaceutical giant Merck & Co and he was being informed that its blockbuster anti-arthritis drug Vioxx was being voluntarily recalled amid concerns it could increase the risk of heart attack.

These precautions, bordering on the clandestine, are indicative of the determination with which Merck & Co went about marketing, promoting and selling Vioxx, which at one point was used by more than 80 million people. More alarming, however, was the way the drug company dealt with obstacles that stood in the way of selling Vioxx and meeting its profit target.

The fairly sterile courtroom 6A at the Federal Court building in Melbourne has been witness for the past three months to a class-action civil trial involving stories of extraordinary marketing tactics and a cast of colourful characters who developed, promoted, protected and, most important, believed in Vioxx.

Lead plaintiff Graeme Peterson, acting on behalf of every Australian who took the drug from its launch in 2001 to its voluntary recall in September 2004, claims that Vioxx contributed to his heart attack in December 2003. He also alleges Merck & Co and its Australian subsidiary, Merck, Sharp and Dohme, knew about the cardiovascular risks of the drug and covered it up.

It is the first civil trial against the pharmaceutical giant outside the US and has been keenly watched by lawyers across the world. The evidence put by both sides and the final outcome of the case will have implications on any potential legal action elsewhere. Merck contends there is no direct medical way of proving its drug could have contributed to a heart attack and there is no marker that it did in Peterson’s case.

Merck settled hundreds of lawsuits over Vioxx in the US for $US4.8 billion in late 2007 but did not admit any liability. Its hired PR guns, who briefed reporters during the early days of the Melbourne trial, claim the settlement occurred purely because of the unique and costly US civil law system, in which juries award compensation.

Therefore the company and its various subsidiaries across the world are prepared to fight every case outside the US, including the Australian civil action, claiming there is no definitive scientific proof that Vioxx caused heart attacks. It also says the marketing techniques were reasonable and based on all the available medical data the company had at the time.

The case has provided a rare peek behind the closed doors of pharmaceutical companies, revealing how they operate and what they will do to get doctors to prescribe their drugs to their patients.

There have been allegations of the creation of a hit list of doctors critical of the drug who needed to be “neutralised”; training sales representatives in a Men in Black-style workshop to overcome doctors’ concerns that Vioxx caused heart attacks; paying nurses to pore through patient records to find potential candidates for the drug; coming up with “cunning plans” to promote Vioxx to doctors; and even faking a medical journal promoting the company’s product.

Other evidence has included the production of educational videos hosted by television personality David Koch spruiking the drug to general practitioners; plans to give away $6million worth of drug samples in one year; bombardment of doctors with hundreds of visits from sales representatives; wining and dining experts in the field; writing songs (“Go Vioxx, go Vioxx, go Vioxx!!!”) to Ricky Martin-style music to motivate sales staff; and setting up a patients’ loyalty program to ensure “compliance” to the drug. They were revealed during the civil trial, which finished this week.

The uneasy relationship between pharmaceutical companies, doctors and researchers also was explored in the case, during which claims were made that Merck paid top scientists to put their name on in-house studies and arthritis specialists were compensated to promote Vioxx to doctors.

... two cardiologists testifying for the plaintiff provided a different view. They argued several medical conditions in the world could not be mechanically explained but still were accepted, including the link between smoking and lung cancer.
Julian Burnside QC, acting for the plaintiff, argued there was enough scientific proof in Merck’s own clinical trials of an association between Vioxx and increased heart attacks.

The other interesting evidence in the case has come from the Merck witnesses. It is not so much what they have said; rather, it is what they haven’t. And who has been put on the stand and who has not.
Most of the key players involved with Vioxx - from the former head of Merck, Sharp and Dohme, Will Delaat, to the head of Merck’s US research arm, Ed Scolnick - were nowhere to be seen.

The remaining Merck witnesses, especially the Australian staff, have all suffered from memory lapses. Back, marketing manager Penny Dobson, sales manager Keiran McAuley and US researcher Alise Reicin all stated they “could not recall”, “can’t comment on the specifics” or simply “couldn’t remember” in response to key questions asked by the plaintiff’s counsel about internal decisions on Vioxx. Their responses and the absence of other key employees have frustrated the plaintiff. Burnside said in his closing address that it was surprising that Dobson, in particular, “did not know much at all”. He also stated Scolnick’s absence from the witness box “was highly significant”.

Delaat did in fact surface to defend Merck & Co during the trial, just in the wrong arena. He appeared on the SBS show Insight as the new chairman of Medicines Australia, defending his former employer. Delaat said Merck did nothing wrong and he could still sleep at night over his involvement with Vioxx.
“I worked for almost 20 years and I know the values of that company in putting patients and patient outcomes first. I think it’s only fair to say that the company acted responsibly at all times,” he told the program.

It is up to Jessup to decide on Merck’s conduct. It will not be an easy task. He retired for deliberations this week and has to consider thousands of tendered documents and evaluate more than three months’ evidence. He has to decide whether Vioxx materially increased the risk of Peterson’s heart attack and whether Merck acted reasonably in its marketing efforts for the drug.

It’s no pointer to an outcome, but Jessup has said in the last days of the case that drug companies were entitled to market their products and be “profit-driven”.
Whatever the outcome, questions have been raised about the conduct of pharmaceutical companies in the marketing of their drugs. What used to be in the realm of popular fiction or conspiracy theorists about the behaviour of big pharmaceuticals has been alleged in the Federal Court as a reality. Merck & Co’s slogan - “Where patients come first” - may invite scepticism.

Read the full article at:,28124,25695247-5018983,00.html

All Vioxx articles from the Australia:,,5018983.html



Media homepage


Pharma Phacts are a medical student group committed to raising awareness about pharmaceutical companies and their interactions with medical students.